NCT05707078 PET/CT Follow up for Head and Neck Squamous Cell Carcinoma
| NCT ID | NCT05707078 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Rigshospitalet, Denmark |
| Condition | Head and Neck Squamous Cell Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 600 participants |
| Start Date | 2023-03-07 |
| Primary Completion | 2028-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 600 participants in total. It began in 2023-03-07 with a primary completion date of 2028-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
PET/CT follow up for Head and Neck Squamous Cell Carcinoma The following is a presentation of a prospective protocol, named PET/CT follow up for Head and Neck Squamous Cell Carcinoma (PET Follow), including patients who have completed radiotherapy treatment for squamous cell carcinoma of the head and neck (HNSCC). The purpose of this study is to investigate the diagnostic performance of 18F-fluorodeoxy-D-glucose (FDG) Positron Emission Tomography/ Computed Tomography (PET/CT) in patients with HNSCC after curative intended treatment.
Eligibility Criteria
Inclusion Criteria: * Informed consent * Age above 18 * Completed curative treatment for HNSCC of the oral cavity, nasopharynx, oropharynx, hypopharynx or larynx Exclusion Criteria: * Patient refusal * Patients with clinical N0 neck * Patients who had neck dissections prior to radiotherapy * Patients who are clinical inoperable for any reason
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05707078 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Head and Neck Squamous Cell Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05707078 currently recruiting?
Yes, NCT05707078 is actively recruiting participants. Contact the research team at jacob.hoeygaard.rasmussen.01@regionh.dk for enrollment information.
Where is the NCT05707078 trial being conducted?
This trial is being conducted at Copenhagen, Denmark.
Who is sponsoring the NCT05707078 clinical trial?
NCT05707078 is sponsored by Rigshospitalet, Denmark. The trial plans to enroll 600 participants.